Carraguard

also known as PC-515

Developed for: HIV infectious disease · chlamydia trachomatis infectious disease · gonorrhea · syphilis · Trichomonas vaginitis urogenital infection · herpes simplex infectious disease
Investigated by: Population Council · Bill and Melinda Gates Foundation · Centers for Disease Control and Prevention · Chiang Rai District Health Office · Chiang Rai Hospital · Chiang Rai Municipal Health Office
+13 more
· Chiang Rai Public Health Office · Ministry of Health, Thailand · National Center for Infectious Diseases · United States Agency for International Development (USAID) · Collaboration (TUC) · FHI 360 · Medical Research Council · Medical Research Council, South Africa · Nat'l Cntr. for HIV, STD, & TB Prevention Atlanta: Division of STD Prevention,Div. of HIV/AIDS Prevention-Surveillance & Epidemiology · National Center for HIV STD and TB Prevention · National Institute of Allergy and Infectious Diseases (NIAID) · University of Cape Town · University of Limpopo

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT00213044	Mar 2003 → Jun 2004	HIV infectious disease	Population Council	Completed	No outcome recorded
Phase 1	NCT00213005	Jun 2002 → Aug 2003	HIV infectious disease	Population Council	Completed	No outcome recorded
Phase 1	NCT00213057	Jun 2001 → Jun 2002	HIV infectious disease, Trichomonas vaginitis urogenital infection, chlamydia trachomatis infectious disease, gonorrhea +1	Population Council	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT00213031	Feb 2000 → Dec 2001	HIV infectious disease, Trichomonas vaginitis urogenital infection, chlamydia trachomatis infectious disease, gonorrhea +2	Population Council	Completed	No outcome recorded
Phase 2	NCT00213018	Oct 1999 → Jan 2002	HIV infectious disease, Trichomonas vaginitis urogenital infection, chlamydia trachomatis infectious disease, gonorrhea +1	Population Council	Completed	No outcome recorded
Phase 31 trial · 1 missed
Phase 3	NCT00213083	Apr 2004 → Apr 2007	AIDS	Population Council	Completed	Missed primary

Every value below carries the sentence it was read from. 7 sources stand behind the page.

Field	Value	Cited text
Known as	Carraguard	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00213044 ↗ 5 NCT00213083 ↗ NCT00213057 ↗ NCT00213005 ↗ NCT00213018 ↗ NCT00213031 ↗
Known as	PC-515	“Carraguard™ (PC-515), the Population Council's lead candidate microbicide, was tested in a randomized, controlled trial” NCT00213044 ↗ 5 “Carraguard™ (PC-515), the Population Council's lead candidate microbicide” NCT00213057 ↗ “Carraguard™ (PC-515), the Population Council's lead candidate microbicide” NCT00213031 ↗ “Carraguard (PC-515)” NCT00213005 ↗ “Carraguard (PC-515)” NCT00213018 ↗ “Carraguard (PC-515)” NCT00213083 ↗
Modality	Other / unclassified	“Carraguard, a carrageenan-based compound developed by the Population Council” PMID 19059048 ↗ Dec 2008
Route	Other	“applied vaginally once per day for 14 days” NCT00213005 ↗
Route	Topical	“applied vaginally once per day for 14 days” NCT00213005 ↗